Mesenchymal
stem cells, also known as Mesenchymal Stromal Cells (MSCs), are
adult, fibroblast-like multipotent cells that can differentiate and
mature into tissues of mesodermal origin such as adipocytes,
chondroblasts, and osteoblasts. Mesenchymal stem cells were isolated
first time from the bone marrow and later from various sources such
as cord cells, adipose tissue, and molar cells. MSCs in terms of
size, are smaller and are quite difficult to observe in histological
sections. A group of mesenchymal stem cells are called as mesenchyme
and is widely distributed in the body. Mesenchymal cells can multiply
in numbers of specialized cells and they can grow in-vitro or in-vivo
condition.
Free
Request Sample of Report:
https://www.coherentmarketinsights.com/insight/request-sample/720
The
mesenchymal stem cells play an important role within an organism for
suppression of immune cells activation, increase the number of newer
cells, reduce cell death or cell damage in the body, and secretion of
both neurotrophic and angiogenic factors, which are responsible for
stabilizing the extracellular matrix, when transplanted to the brain,
this cells promote the reduction of free radical levels and enhance
synaptic connections of damaged neurons, and increases the
myelination of axons. The mesenchymal cells are also able to replace
and repair any damaged blood vessel in the cerebrum brain.
Rise
in prevalence of osteoporosis and increase in cancer incidences are
expected to support the global market growth
MSCs
have the ability to grow bone tissues through the bone surface to
form new bone, which in turn has the potency to treat osteoporosis.
According to the National Institute of Health (NIH), in 2015, the
U.S. accounted for around 53 million people suffering from
osteoporosis or at a high risk due to low bone mass.
According
to Osteoporosis Canada, around 1 in 5 men and 1 in 3 women suffer
from osteoporotic fracture during their lifetime, whereas
osteoporosis causes around 70-90% of 30,000 hip fractures yearly; the
annual cost to Canada for treating osteoporosis was around US$ 4.0
billion in the year 2012, which is expected to rise in the upcoming
years. Furthermore, according to the International Osteoporosis
Foundation (IOF), annually around 9.0 million people worldwide are
suffering from osteoporosis fractures. The aforementioned factors are
expected to bolster the Mesenchymal stem cells market growth over the
forecast period.
Mesenchymal
Stem Cells Market Players
Some
of the key market players identified across the value chain of
mesenchymal stem cells market are, Pluristem Therapeutics,
LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis,
Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences,
Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex
Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori
Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California
Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation
Inc.
Mesenchymal
Stem Cells Market Taxonomy
On
the basis of product type, the global Mesenchymal Stem Cells Market
is segmented into:
-
Human MSCs
-
Mouse MSCs
-
Rat MSCs
-
Others
On
the basis of application, the global Mesenchymal Stem Cells Market is
segmented into:
-
Drug discovery and development
-
Injuries
-
Cardiovascular and myocardial infarction
-
Others
Browse
In-Depth Analysis Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/mesenchymal-stem-cells-market-720
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment